- Conditions
- Solid Tumor Malignancies, Colorectal Carcinoma, Small Cell Lung Cancer ( SCLC ), Head and Neck (HNSCC), Bladder Cancer, Non-Small Cell Lung Cancer, Pancreatic Cancer, Advanced or Metastatic
- Interventions
- CP-383
- Drug
- Lead sponsor
- Tasca Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 13
- States / cities
- Denver, Colorado • Orlando, Florida • Grand Rapids, Michigan + 10 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1057–1080
of 1,584
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Overactive Bladder
- Interventions
- fesoterodine fumarate
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 516 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007
- U.S. locations
- 24
- States / cities
- Homewood, Alabama • Huntsville, Alabama • La Mesa, California + 20 more
- Conditions
- Overactive Bladder, Urge Incontinence, Fecal Incontinence
- Interventions
- Lidocaine patch, Placebo
- Drug · Other
- Lead sponsor
- University of Louisville
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 39 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 2
- States / cities
- Louisville, Kentucky
- Conditions
- Interstitial Cystitis, Painful Bladder Syndrome
- Interventions
- Mycophenolate Mofetil, Mycofenolate Mofetil (MMF), Placebo
- Drug
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 210 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 10
- States / cities
- San Diego, California • Stanford, California • Maywood, Illinois + 7 more
- Conditions
- Prostate Cancer, Bladder Cancer, Non-small Cell Lung Cancer, Esophageal Cancer, Sarcoma
- Interventions
- NY-ESO-1 Plasmid DNA Cancer Vaccine
- Biological
- Lead sponsor
- Ludwig Institute for Cancer Research
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 2
- States / cities
- New York, New York • Houston, Texas
- Conditions
- Overactive Bladder
- Interventions
- Behavioral training, Oxybutynin chloride, extended-release
- Behavioral · Drug
- Lead sponsor
- US Department of Veterans Affairs
- Federal
- Eligibility
- 19 Years and older · Male only
- Enrollment
- 143 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2009
- U.S. locations
- 2
- States / cities
- Birmingham, Alabama • Decatur, Georgia
- Conditions
- Overactive Bladder
- Interventions
- Botulinum Toxin Type A 300U, Botulinum Toxin Type A 200U
- Biological
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 397 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 1
- States / cities
- Middlebury, Connecticut
- Conditions
- Urothelial Carcinoma
- Interventions
- Atezolizumab, Guadecitabine
- Drug
- Lead sponsor
- Fox Chase Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 3
- States / cities
- Los Angeles, California • Baltimore, Maryland • Philadelphia, Pennsylvania
- Conditions
- Lower Urinary Tract Symptoms, Overactive Bladder
- Interventions
- Fully integrated Uro-NIRS:UDS
- Device
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Bladder Cancer
- Interventions
- Not listed
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 30 Years to 79 Years
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2020
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Bladder Cancer
- Interventions
- Extracorporeal Urinary Diversion, Intracorporal Urinary Diversion
- Procedure
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Bladder Cancer
- Interventions
- Bladder tumor biopsy
- Procedure
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Cancer Harboring BRAF Alterations, HGG, LGG, Solid Tumors
- Interventions
- Plixorafenib
- Drug
- Lead sponsor
- Fore Biotherapeutics
- Industry
- Eligibility
- 8 Years and older
- Enrollment
- 254 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 30
- States / cities
- Beverly Hills, California • San Francisco, California • Westwood, Los Angeles, California + 23 more
- Conditions
- Bladder Cancer, Prostate Cancer
- Interventions
- Multiphoton microscopy
- Other
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 21 Years to 85 Years
- Enrollment
- 344 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2015
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Urinary Bladder, Overactive, Urinary Incontinence, Urge
- Interventions
- eLearning
- Other
- Lead sponsor
- Kathleen O'Connell
- Other
- Eligibility
- 40 Years to 64 Years · Female only
- Enrollment
- 90 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Stress Urinary Incontinence, Urge Incontinence, Urge and Stress, Overactive Bladder
- Interventions
- BTL EMSELLA Active treatment, BTL EMSELLA Sham Treatment
- Device
- Lead sponsor
- Boston Urogynecology Associates
- Other
- Eligibility
- 18 Years to 100 Years · Female only
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 1
- States / cities
- Cambridge, Massachusetts
- Conditions
- Breast Cancer, Bladder Cancer, Kidney Cancer, Colon Cancer, Prostate Cancer, Lung Cancer, Ovarian Cancer
- Interventions
- PCR/PCR/LDR Strategy
- Genetic
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 21,081 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2027
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma, Locally Advanced Ureter Urothelial Carcinoma, Locally Advanced Urethral Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Renal Pelvis Urothelial Carcinoma, Metastatic Ureter Urothelial Carcinoma, Metastatic Urethral Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Recurrent Bladder Urothelial Carcinoma, Recurrent Renal Pelvis Urothelial Carcinoma, Recurrent Ureter Urothelial Carcinoma, Recurrent Urethral Urothelial Carcinoma, Recurrent Urothelial Carcinoma, Stage III Bladder Cancer AJCC v8, Stage III Renal Pelvis Cancer AJCC v8, Stage III Ureter Cancer AJCC v8, Stage III Urethral Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8, Stage IIIB Bladder Cancer AJCC v8, Stage IV Bladder Cancer AJCC v8, Stage IV Renal Pelvis Cancer AJCC v8, Stage IV Ureter Cancer AJCC v8, Stage IV Urethral Cancer AJCC v8, Stage IVA Bladder Cancer AJCC v8, Stage IVB Bladder Cancer AJCC v8, Unresectable Bladder Urothelial Carcinoma, Unresectable Renal Pelvis Urothelial Carcinoma, Unresectable Ureter Urothelial Carcinoma, Unresectable Urethral Urothelial Carcinoma, Unresectable Urothelial Carcinoma
- Interventions
- Diagnostic Laboratory Biomarker Analysis, Nivolumab, Relatlimab
- Other · Biological · Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Bladder Cancer, Bladder Tumor, Muscle-Invasive Bladder Cancer
- Interventions
- Nivolumab, Radical cystectomy (RC), Bempegaldesleukin
- Biological · Procedure
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 114 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 15
- States / cities
- Gilbert, Arizona • Tucson, Arizona • La Jolla, California + 12 more
- Conditions
- Head and Neck Neoplasms, Lung Neoplasms, Urinary Bladder Neoplasms, Breast Neoplasms
- Interventions
- [F-18]-5-FLUORO-2'-DEOXYCYTIDINE, Tetrahydrouridine intravenous (IV), Tetrahydrouridine (oral), Positron emission tomography (PET)/Computed tomography (CT)
- Drug · Diagnostic Test
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2019
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Urology, Urinary Bladder, Overactive, Benign Prostatic Hyperplasia, Urodynamics, Home Monitoring, Urinary Incontinence (UI), Lower Urinary Tract Dysfunction
- Interventions
- Glean Urodynamics System
- Device
- Lead sponsor
- Bright Uro
- Industry
- Eligibility
- 22 Years and older
- Enrollment
- 101 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 9
- States / cities
- New Orleans, Louisiana • Hanover, Maryland • Owings Mills, Maryland + 6 more
- Conditions
- Overactive Bladder
- Interventions
- dexmecamylamine, Placebo
- Drug
- Lead sponsor
- Targacept Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,635 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 125
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 109 more
- Conditions
- Neurogenic Bladder, Multiple Sclerosis, Voiding Dysfunction
- Interventions
- Transcranial Rotating Permanent Magnet Stimulator (TRPMS)
- Device
- Lead sponsor
- The Methodist Hospital Research Institute
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Overactive Bladder
- Interventions
- DR-3001, Placebo
- Drug
- Lead sponsor
- Duramed Research
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 1,104 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2010
- U.S. locations
- 81
- States / cities
- Huntsville, Alabama • Mobile, Alabama • Montgomery, Alabama + 68 more